title: Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.
abstract: BACKGROUND
  Irinotecan hydrochloride, a topoisomerase I inhibitor, has been preliminarily recognized as an effective agent against clear cell carcinoma of the ovary (CCC), but there are few clinical data. Our aim was to compare progression-free survival (PFS) between patients treated with irinotecan hydrochloride and cisplatin (CPT-P) and those with treated with paclitaxel and carboplatin (TC).
  
  
  METHODS
  One hundred and seventeen patients at International Federation of Gynecology and Obstetrics (FIGO) stages Ic (ascites/malignant washing) - IV were identified by scanning the medical records of ten Japanese hospitals. After complete surgical staging procedures including lymphadenectomy, 35 patients received CPT-P and 82 patients received TC. The PFS and overall survival of the two groups were compared using the Kaplan-Meier method.
  
  
  RESULTS
  There was no significant difference in median age, performance status, FIGO stage, rate of optimal cytoreduction, or follow-up period between the CPT-P and TC groups. Two-year and 5-year PFS was 48% and 40%, respectively, in the TC group and 55% and 55%, respectively, in the CPT-P group (P = 0.31). Multiple regression analysis revealed that only residual tumor was an independent prognostic factor for PFS (P < 0.01).
  
  
  CONCLUSIONS
  CPT-P showed a potential therapeutic effect, at least no less than that of TC therapy. Although there was no significant survival benefit in the present retrospective analysis, we recommend that the CPT-P regimen be evaluated in a larger, prospective, clinical trial.
authors: Department of Obstetrics and Gynecology, National Defense Medical College, Namiki 3-2, Tokorozawa, Saitama, 359-8513, Japan. mastkn@ndmc.ac.jp
authors: Masashi
authors: M
authors: Takano
authors: Toru
authors: T
authors: Sugiyama
authors: Nobuo
authors: N
authors: Yaegashi
authors: Mitsuaki
authors: M
authors: Suzuki
authors: Hiroshi
authors: H
authors: Tsuda
authors: Satoru
authors: S
authors: Sagae
authors: Yasuhiro
authors: Y
authors: Udagawa
authors: Kazuo
authors: K
authors: Kuzuya
authors: Junzo
authors: J
authors: Kigawa
authors: Satoshi
authors: S
authors: Takeuchi
authors: Hitoshi
authors: H
authors: Tsuda
authors: Takuya
authors: T
authors: Moriya
authors: Yoshihiro
authors: Y
authors: Kikuchi
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D000077146:Irinotecan; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin; D002166:Camptothecin
references: Int J Gynecol Cancer. 2006 Jan-Feb;16(1):52-6
references: 16445610
references: Jpn J Cancer Res. 2002 Jun;93(6):723-8
references: 12079522
references: Cancer Lett. 1998 Jun 19;128(2):211-8
references: 9683285
references: Int J Gynecol Cancer. 2003 Nov-Dec;13(6):735-40
references: 14675308
references: Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6880-8
references: 16203778
references: Gynecol Oncol. 2004 Jul;94(1):197-203
references: 15262142
references: Am J Pathol. 2003 Dec;163(6):2503-12
references: 14633622
references: Gynecol Oncol. 1996 Mar;60(3):412-7
references: 8774649
references: Br J Cancer. 2006 May 22;94(10):1369-74
references: 16641903
references: Int J Cancer. 1992 Feb 20;50(4):604-10
references: 1537625
references: Gynecol Oncol. 2005 Jun;97(3):893-7
references: 15894369
references: Gynecol Oncol. 2003 Mar;88(3):394-9
references: 12648592
references: Gynecol Oncol. 2006 Aug;102(2):285-91
references: 16516283
references: Cancer. 2000 Jun 1;88(11):2584-9
references: 10861437
references: N Engl J Med. 2002 Jan 10;346(2):85-91
references: 11784874
references: N Engl J Med. 1996 Jan 4;334(1):1-6
references: 7494563
references: Cancer. 1996 Nov 15;78(10):2157-63
references: 8918409
references: Jpn J Clin Oncol. 1999 Sep;29(9):434-7
references: 10563197
references: Oncol Rep. 2000 Mar-Apr;7(2):327-31
references: 10671681
references: Cancer Res. 1996 Feb 15;56(4):789-93
references: 8631015
references: J Clin Oncol. 1991 Jul;9(7):1138-50
references: 1904477
references: Jpn J Cancer Res. 1994 Sep;85(9):966-71
references: 7961127
references: Gynecol Oncol. 1993 May;49(2):250-4
references: 8504995